Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Lexaria Bioscience Corp. - Common Stock (NQ:LEXX)

0.9700 -0.0400 (-3.96%)
Streaming Delayed Price Updated: 12:15 PM EDT, May 19, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Lexaria Bioscience Corp. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
30 31 Next >
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Noteworthy Findings from Interim Results of Ongoing Diabetes Animal Study
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
Lexaria Bioscience Corp. (NASDAQ: LEXX) Reports Issuance of Three New Patents, Growing Portfolio to 46 Granted Patents Worldwide
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
Positive Interim Body Weight Results from Lexaria's Diabetes Animal Study
Via ACCESSWIRE
TinyGemsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Makes Management Announcement, Plans for Strategic Growth
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
Lexaria Preparing For Strategic Growth
Via ACCESSWIRE
Dosing is Complete in Lexaria's Second GLP-1 Human Pilot Study
Via ACCESSWIRE
Lexaria Bioscience Corp. (NASDAQ: LEXX) Looking to Replicate Results from First GLP-1 Study Following CRO Contract Award for 12-Week Chronic Human Study
Via Investor Brand Network
LEXX Stock Earnings: Lexaria Bioscience Misses EPS, Misses Revenue for Q3 2024
LEXX stock results show that Lexaria Bioscience missed analyst estimates for earnings per share and missed on revenue for the third quarter of 2024. 
Via InvestorPlace
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Completes Dosing in Second GLP-1 Human Pilot Study
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property Product Safety
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Completes Dosing in Second GLP-1 Human Pilot Study
Via CannabisNewsWire
Topics Intellectual Property
Exposures Intellectual Property Product Safety
Lexaria Receives New Patents For Antiviral Drug Delivery and for Treating Epilepsy
Via ACCESSWIRE
Lexaria Awards CRO Contract for 12-Week DehydraTECH GLP-1 Chronic Human Study
Via ACCESSWIRE
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Secures New Patents for Antiviral Drug Delivery, Treating Epilepsy
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
TinyGemsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Eyeing Favorable Strategic Partnering with Leading GLP-1 Players
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
Lexaria Bioscience Corp. (NASDAQ: LEXX) Completes Second Round of Dosing for Human Pilot Study #2; Set to Complete Third Study Arm in Early July
Via Investor Brand Network
Dosing Continues in Lexaria’s Second GLP-1 Human Pilot Study
Via ACCESSWIRE
7 A-Rated Penny Stocks to Beat June Gloom
Some penny stocks can be diamonds in the rough. These A-rated penny stocks are all solid picks for a portfolio this month. 
Via InvestorPlace
HempNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Engages CRO for DehydraTECH GLP-1 Human Study
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
Lexaria Bioscience Corp. (NASDAQ: LEXX) Hires CRO; Set for First Tirzepatide Molecule Study
Via Investor Brand Network
7 A-Rated Biotech Stocks Worth Betting on in June
A-rated biotech stocks are highly coveted because they are at the forefront – or in the midst of -- groundbreaking innovation. 
Via InvestorPlace
Lexaria Bioscience Corp. (NASDAQ: LEXX) Grows Patent Portfolio to 43 Granted Patents Worldwide
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Reports Completion of Dosing in Second Arm of Third GLP-1 Human Pilot Study
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property Product Safety
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Reports Completion of Dosing in Second Arm of Third GLP-1 Human Pilot Study
Via CannabisNewsWire
Topics Intellectual Property
Exposures Intellectual Property Product Safety
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
It's time to start Tuesday with a breakdown of the biggest pre-market stock movers traders will want to know about this morning! 
Via InvestorPlace
Why HealthEquity Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
7 A-Rated Penny Stocks Work Betting On in H2 2024
For a growth investor, one of the top advantages of A-rated penny stocks is that they have the potential for oversized profits. 
Via InvestorPlace
Lexaria Bioscience Corp. (NASDAQ: LEXX) Concludes First Dosing for its Second GLP-1 Human Pilot Study; Maintains Study Pace and Rollout for 2024
Via CannabisNewsWire
Lexaria Bioscience Corp. (NASDAQ: LEXX) Concludes First Dosing for its Second GLP-1 Human Pilot Study; Maintains Study Pace and Rollout for 2024
Via Investor Brand Network
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Selects CRO in Third GLP-1 Human Pilot Study
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
< Previous 1 2 3 4 5 6 7 8 9
...
30 31 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.